Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 21, 2021 - Issue 1
Submit an article Journal homepage
462
Views
6
CrossRef citations to date
0
Altmetric
Review

Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?

Giancarlo Comia Institute of Experimental Neurology of San Raffaele Hospital, Milan, ItalyCorrespondence[email protected]
View further author information
,
Gloria Dalla Costaa Institute of Experimental Neurology of San Raffaele Hospital, Milan, Italy;b Vita-Salute San Raffaele University, Milan, ItalyView further author information
&
Lucia Moiolaa Institute of Experimental Neurology of San Raffaele Hospital, Milan, Italy;c Neurology Unit and MS Center, San Raffaele Hospital, Milan, ItalyORCID Iconhttps://orcid.org/0000-0001-6313-4952View further author information
ORCID Icon
Pages 21-34 | Received 20 Jul 2020, Accepted 24 Sep 2020, Published online: 10 Oct 2020

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

G. Dalla Costa, L. Leocani & G. Comi. (2022) Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis. Expert Review of Clinical Immunology 18:2, pages 105-114.
Read now
Susana Otero-Romero, Adrián Sánchez-Montalvá & Angela Vidal-Jordana. (2021) Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. Expert Review of Clinical Immunology 17:3, pages 285-300.
Read now

Articles from other publishers (4)

Marianna G. Rispoli, Maria D’Apolito, Valeria Pozzilli & Valentina Tomassini. 2023. Precision Medicine in Neurodegenerative Disorders, Part II. Precision Medicine in Neurodegenerative Disorders, Part II 293 311 .
Samira Luisa Pereira Apóstolos, Mateus Boaventura, Natalia Trombini Mendes, Larissa Silva Teixeira & Igor Gusmão Campana. (2022) How to choose initial treatment in multiple sclerosis patients: a case-based approach. Arquivos de Neuro-Psiquiatria 80:5 suppl 1, pages 159-172.
Crossref
Gianmarco Abbadessa, Giuseppina Miele, Paola Cavalla, Paola Valentino, Girolama Alessandra Marfia, Elisabetta Signoriello, Doriana Landi, Chiara Bosa, Marco Vercellino, Antonio De Martino, Rosanna Missione, Maddalena Sparaco, Luigi Lavorgna, Giacomo Lus & Simona Bonavita. (2021) CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab. International Journal of Environmental Research and Public Health 18:15, pages 8163.
Crossref
Vikram Bhise & Suhayl Dhib-Jalbut. (2021) Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives. Neurotherapeutics 18:1, pages 244-251.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.